PML regulates p53 acetylation and premature senescence induced by oncogenic Ras

The tumour suppressor p53 induces cellular senescence in response to oncogenic signals. p53 activity is modulated by protein stability and post-translational modification, including phosphorylation and acetylation. The mechanism of p53 activation by oncogenes remains largely unknown. Here we report that the tumour suppressor PML regulates the p53 response to oncogenic signals. We found that oncogenic Ras upregulates PML expression, and overexpression of PML induces senescence in a p53-dependent manner. p53 is acetylated at lysine 382 upon Ras expression, an event that is essential for its biological function. Ras induces re-localization of p53 and the CBP acetyltransferase within the PML nuclear bodies and induces the formation of a trimeric p53-PML-CBP complex. Lastly, Ras-induced p53 acetylation, p53-CBP complex stabilization and senescence are lost in PML-/- fibroblasts. Our data establish a link between PML and p53 and indicate that integrity of the PML bodies is required for p53 acetylation and senescence upon oncogene expression.     

p53突变蛋白下调调控人肺腺癌细胞中E-cadherin的表达并促进细胞迁移

摘要：p53 是最重要的抑癌基因之一。在肿瘤发生发展过程中,超过50% 的人类肿瘤组织和细胞中存在 p53 基因发生突变,而且大多数为点突变,其中包括 R273H,由此产生的点突变蛋白会失去 p53 的DNA结合和特异的转录活性。最近的研究表明p53突变蛋白还可能获得一些野生型p53蛋白不具有的新的生物学活性。在本研究中,我们在人肺肿瘤细胞 H1299 中稳定表达含R273H 点突变的p53 蛋白（p53-R273H）,观察到细胞中 E-cadherin mRNA 和蛋白水平下调,同时细胞迁移能力增强。免疫荧光方法检测发现 p53-R273H 显著降低 E-cadherin 在肿瘤细胞间的表达。这些结果表明p53-R273H 突变蛋白具有下调 E-cadherin 基因的表达和促使肿瘤细胞迁移的新功能。     

基于原子力显微镜研究p53蛋白与PBR322 DNA的相互作用

肿瘤(癌症)是由于细胞在复制过程中,DNA损伤不能修复导致细胞凋亡或者细胞无限增殖而形成的。DNA在细胞中转录和翻译都会涉及蛋白与DNA的结合,肿瘤抑制蛋白也是参与这一过程的关键蛋白之一。然而,众多研究发现,肿瘤抑制蛋白p53具有识别和修复损伤DNA的效果,对于细胞的凋亡、基因的保护和避免癌症发生有着重要的意义。有研究表明,金属镁离子和锌离子可以增强p53蛋白的结构稳定性和p53-DNA的亲和力。因此,我们基于原子力显微镜(AFM),直观地呈现出p53蛋白与PBR322环状DNA相互作用的图像,同时发现p53蛋白可以使环状DNA自身形成聚集或者相交。但是,对于长度相当的5 000bp的线状DNA几乎没有这样的效果,而对于20 000bp DNA不会出现这样的现象。然而,在高浓度镁离子环境下,环状DNA会扭转成为麻花状,即形成超螺旋结构。这一现象,可为p53蛋白功能和作用机理研究提供指导,也为癌症治疗、癌症药物开发以及癌症检测方法提供启发。     

Quantitative detection of ING1 mRNA under different gene regulation based on molecular beacon

As an important tumor suppressor, normal expres- sion of ING1 is associated with the maintenance of cell normal physiological functions. Its low expression of- ten causes aberrant events of cell survive, growth and differentiation[1] which results in loss…     

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

The p53 gene is frequently inactivated in human cancers. Here we have isolated a p53-inducible gene, p53R2, by using differential display to examine messenger RNAs in a cancer-derived human cell line carrying a highly regulated wild-type p53 expression system. p53R2 contains a p53-binding sequence in intron 1 and encodes a 351-amino-acid peptide with striking similarity to the ribonucleotide reductase small subunit (R2), which is important in DNA synthesis during cell division. Expression of p53R2, but not R2, was induced by ultraviolet and gamma-irradiation and adriamycin treatment in a wild-type p53-dependent manner. Induction of p53R2 in p53-deficient cells caused G2/M arrest and prevented cells from death in response to adriamycin. Inhibition of endogenous p53R2 expression in cells that have an intact p53-dependent DNA damage checkpoint reduced ribonucleotide reductase activity, DNA repair and cell survival after exposure to various genotoxins. Our results indicate that p53R2 encodes a ribonucleotide reductase that is directly involved in the p53 checkpoint for repair of damaged DNA. The discovery of p53R2 clarifies a relationship between a ribonucleotide reductase activity involved in repair of damaged DNA and tumour suppression by p53.     

p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage.

The protein p73 is a structural and functional homologue of the p53 tumour-suppressor protein but, unlike p53, it is not induced in response to DNA damage. The tyrosine kinase c-Abl is activated by certain DNA-damaging agents and contributes to the induction of programmed cell death (apoptosis) by p53-dependent and p53-independent mechanisms. Here we show that c-Abl binds to p73 in cells, interacting through its SH3 domain with the carboxy-terminal homo-oligomerization domain of p73. c-Abl phosphorylates p73 on a tyrosine residue at position 99 both in vitro and in cells that have been exposed to ionizing radiation. Our results show that c-Abl stimulates p73-mediated transactivation and apoptosis. This regulation of p73 by c-Abl in response to DNA damage is also demonstrated by a failure of ionizing-radiation-induced apoptosis after disruption of the c-Abl-p73 interaction. These findings show that p73 is regulated by a c-Abl-dependent mechanism and that p73 participates in the apoptotic response to DNA damage.     

p53振子的形成机制及microRNA对p53目标基因表达的精细调控

肿瘤抑制因子p53调控着大量的基因,在肿瘤抑制中起着关键作用.实验结果表明,当DNA受损后,p53的表达呈现周期性振荡.已有的一些p53振子的理论模型,其振子产生机制通常依赖于p53和Mdm2之间相互作用的时滞因素.考虑基因表达的转录和翻译过程,运用动力学方程建模的方法,给出一种新模型,并利用Hopf分叉理论,给出p53振子产生的条件.数值模拟结果表明,与已有的时滞模型相比,该模型对参数具有更好的鲁棒性,较好地解释了p53振子的产生机制.最近的许多实验表明,p53调控着miR-34家族中大量microRNA的表达,这些microRNA又在后转录水平上对p53的下游目标基因起着调控作用.在这一模型基础上,研究microRNA加入p53调控网络后所起的调控作用,数值模拟结果初步表明,microRNA对p53下游目标基因表达起到了精细调控作用.     

p53蛋白与肝细胞癌临床病理特征及预后的关系

目的 探讨p53蛋白表达与肝细胞癌的临床病理特征及预后的关系,为术后综合治疗及判断预后提供依据。方法 采用免疫组织化学方法检测88例肝细胞癌组织中p53蛋白的表达,比较阳性患者和阴性患者的临床病理因素和术后累积复发率、术后累积生存率的差异。结果 p53蛋白表达阳性组1、2、3累积生存率分别为75．0％、54.4%、24．2％,阴性组相应的分别为84．3％、77．8％、56．1％。与阴性组相比,p53蛋白阳性组有较高的术前AFP浓度（P=0．005）、有较大的肿瘤最大直径（P=0．042）、肿瘤包膜不完整或无包膜者多见（P=0．023）。结论 p53蛋白是评价肝细胞癌恶性程度及预后的一个有价值的生物学指标。     

Role of genomic instability and p53 in AID-induced c-myc-Igh translocations

Chromosomal translocations involving the immunoglobulin switch region are a hallmark feature of B-cell malignancies. However, little is known about the molecular mechanism by which primary B cells acquire or guard against these lesions. Here we find that translocations between c-myc and the IgH locus (Igh) are induced in primary B cells within hours of expression of the catalytically active form of activation-induced cytidine deaminase (AID), an enzyme that deaminates cytosine to produce uracil in DNA. Translocation also requires uracil DNA glycosylase (UNG), which removes uracil from DNA to create abasic sites that are then processed to double-strand breaks. The pathway that mediates aberrant joining of c-myc and Igh differs from intrachromosomal repair during immunoglobulin class switch recombination in that it does not require histone H2AX, p53 binding protein 1 (53BP1) or the non-homologous end-joining protein Ku80. In addition, translocations are inhibited by the tumour suppressors ATM, Nbs1, p19 (Arf) and p53, which is consistent with activation of DNA damage- and oncogenic stress-induced checkpoints during physiological class switching. Finally, we demonstrate that accumulation of AID-dependent, IgH-associated chromosomal lesions is not sufficient to enhance c-myc-Igh translocations. Our findings reveal a pathway for surveillance and protection against AID-dependent DNA damage, leading to chromosomal translocations.     

High frequency of p53 intronic point mutations in laryngeal squamous cell carcinoma

Intronic point mutations are rare and totally unknown for human laryngeal squamous cell carcinoma (LSCC). To explore the relationship of p53 gene intronic mutation to the development of human LSCC, DNA was extracted from both tumor tissues and matched normal tissues of 55 patients with LSCC in northeast of China. Polymerase chain reaction amplification-single strand conformational polymorphism (PCR-SSCP) combined with silver staining and DNA direct sequencing were used to detect mutations in exons 7～8 (p53E7 and p53E8) and introns 7～8 (p53I7 and p53I8) of p53 gene. The p53E7 mutation was detected in 17 out of 55 patients, and the p53I7 mutation in 21 patients. No mutation was found at p53E8 or p53I8 site. The difference between tumor group and paired normal group on the rates of both p53E7 and p53I7 mutations was statistically significant. The rate of p53I7 mutations in tumor tissue was higher than that of normal tissue, and so was that of p53E7. Sequence analysis revealed that most p53I7 mutations were at the nucleotides in the branch point sequence or the polypyrimidine tract in the 3′-splice acceptor site of the intron 7. The high incidence of p53 gene intronic mutation in LSCC indicates that genetic changes within the noncoding region of the p53 gene may serve as an alternative mechanism of activating the pathogenesis of human laryngeal squamous cell carcinoma. Mutations in the noncoding region of this gene should be further studied.     

Interaction of hepatitis B virus with tumor suppressor gene p53: its significance and biological function

The mechanism of the interaction of hepatitis B virus (HBV) with tumor suppressor p53 and its role in the hepatocar-cinogenesis have been studied by PCR-directed sequencing, gel shift assays and in situ ultraviolet cross-linking assay. The biological function of the interaction of HBV with p53 gene was investigated by co-transfection of chloramphenicol acetyltransferase ( CAT) reporter gene. p53 and HBV DNA. and quantitative PCR. Among the 16 primary hepatocellular carcinoma (PHC) samples. 13 were HBV-DNA positive. 10 HBxAg positive and 9 p53 protein positive. The p53 gene point mutation was found in 5 samples, one of which had a G to T substitution located at codon 249. After analyzing the HBV genome by a computer program, a p53 response element binding sequence was found in HBV genome at upstream of enhancer I. from 1047 to 1059 nucleotides. This sequence could specifically bind to p53 protein, increase p53 protein accumulation in the PHC cells and stimulate the transactivating activity of p53 and HBV replication . The results also revealed that HBxAg could combine with p53 protein to form a complex in the cells and enhance CAT expression. Immunocytochemical staining showed that p53 protein complex was located in the cytoplasm and the process of p53 entry to nuclei was. in part, blocked. From our results, we conclude that the mutation of p53 gene at codon 249 is infrequent in HBV-associated PHC. the DNA-protein binding between HBV and p53. and the protein-protein binding between HBxAg and p53 might lead to the reduction or inactivation of p53 protein, which in turn resulting in HBV-associated hepatocarcinogenesis.     

Virus-mediated killing of cells that lack p53 activity

A major goal of molecular oncology is to identify means to kill cells lacking p53 function. Most current cancer therapy is based on damaging cellular DNA by irradiation or chemicals. Recent reports support the notion that, in the event of DNA damage, the p53 tumour-suppressor protein is able to prevent cell death by sustaining an arrest of the cell cycle at the G2 phase. We report here that adeno-associated virus (AAV) selectively induces apoptosis in cells that lack active p53. Cells with intact p53 activity are not killed but undergo arrest in the G2 phase of the cell cycle. This arrest is characterized by an increase in p53 activity and p21 levels and by the targeted destruction of CDC25C. Neither cell killing nor arrest depends upon AAV-encoded proteins. Rather, AAV DNA, which is single-stranded with hairpin structures at both ends, elicits in cells a DNA damage response that, in the absence of active p53, leads to cell death. AAV inhibits tumour growth in mice. Thus viruses can be used to deliver DNA of unusual structure into cells to trigger a DNA damage response without damaging cellular DNA and to selectively eliminate those cells lacking p53 activity.